Organogenesis inked a three-phase agreement with China's National Tissue Engineering Center (NTEC) to advance its products in that country.
The first phase of the partnership will include the commercialization and exportation of existing Organogenesis technology in the Chinese market and eventually throughout Asia. Wound healing and scars are the initial focus of the agreement. Performance milestones, however, may expand the scope of the agreement to include broader surgical uses.
Phase two will encompass the manufacturing of existing Organogenesis cell therapies in Shanghai. The final phase will entail the codevelopment of new technologies, which may be custom-designed for Chinese market needs. Organogenesis will hold the commercial rights for all Western markets for any resulting products.
The NTEC is a central government-funded private company that employs more than 70 scientists and teams of regulatory, production, and commercial professionals.